Ratings by Lucid Capital Markets (Christopher Liu)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/28/2026 | Sensei Biotherapeutics | SNSE | New Coverage | Buy (N/A) |
16.65 (13.85) |
-16.82% | Details | |
| 5/11/2026 | NextCure Inc. | NXTC | New Coverage | Buy (N/A) |
9.76 (2.02) |
-79.3% | Details | |
| 3/2/2026 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
4.56 (6.73) |
47.59% | Details | |
| 2/4/2026 | Tvardi Therapeutics Inc | TVRD | Upgrade | Buy (Neutral) |
3.95 (2.63) |
-33.42% | Details | |
| 1/29/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Buy (N/A) |
3.47 (10.10) |
191.07% | Details | |
| 1/6/2026 | Actuate Therapeutics | ACTU | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2025 | Innate Pharma S.A. | IPHA | New Coverage | Buy (N/A) |
2.09 (1.81) |
-13.4% | Details | |
| 9/26/2025 | Lyell Immunopharma | LYEL | New Coverage | Buy (N/A) |
12.72 (12.74) |
0.16% | Details | |
| 9/18/2025 | Adagene Inc | ADAG | New Coverage | Buy (N/A) |
2.04 (3.94) |
93.14% | Details | |
| 7/21/2025 | Genelux Corp. | GNLX | New Coverage | Buy (N/A) |
3.33 (2.97) |
-10.81% | Details | |
| 5/14/2025 | Exelixis | EXEL | Maintain | Neutral (N/A) |
|
Details | ||
| 4/30/2025 | Tvardi Therapeutics Inc | TVRD | New Coverage | Buy (N/A) |
23.00 (3.95) |
-82.83% | Details | |
| 4/9/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2025 | Cargo Therapeutics | CRGX | Downgrade | Neutral (Buy) |
13.19 (4.47) |
-66.11% | Details | |
| 1/27/2025 | Perspective Therapeutics Inc | CATX | Maintain | Buy (N/A) |
|
Details |
